Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tozorakimab device comparison in healthy volunteers
NCT06908577Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of tozorakimab (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under concentration-time curve from time 0 to infinity, Area under concentration-curve from time 0 to the last quantifiable concentration and 1 more. Started Apr 2025; status: completed.
02
Drugs
tozorakimab
Beyond the preview
Go deeper on NCT06908577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06908577.